Mechanism of Gzma-mediated GEF-H1 activation in intestinal epithelial cells leading to intestinal barrier dysfunction in sepsis.
Summary
The study defines a mechanistic Gzma→GEF‑H1→RhoA/ROCK cascade that disrupts intestinal epithelial barriers in sepsis and demonstrates that pharmacologic inhibition of GEF‑H1 (Epothilone A) restores barrier integrity and improves survival in CLP sepsis. GEF‑H1 genetic deletion was protective, substantiating the target.
Key Findings
- Gzma levels increased in sepsis and correlated with disease severity in human samples and CLP mice.
- Gzma dephosphorylated GEF‑H1 at Ser886, activating RhoA/ROCK, reducing tight junction proteins, lowering TEER, and increasing paracellular permeability.
- GEF‑H1 knockout protected against intestinal injury and improved survival; pharmacologic modulation with Epothilone A restored barrier integrity and improved survival in septic mice.
Clinical Implications
GEF‑H1 emerges as a therapeutic target for gut barrier protection in sepsis; repurposing Epothilone A or developing selective GEF‑H1 inhibitors could be explored in early-phase trials alongside standard care.
Why It Matters
Identifies a first-in-pathway, targetable mechanism linking immune protease signaling to epithelial barrier failure with in vivo rescue, paving a translational path for barrier-protective therapies in sepsis.
Limitations
- Translational relevance to human clinical outcomes remains to be tested in interventional trials
- Potential off-target and safety considerations for Epothilone A require rigorous toxicology and dosing studies
Future Directions
Develop selective GEF‑H1 inhibitors; evaluate barrier-protective therapy in early-phase human trials with pharmacodynamic biomarkers (TEER surrogates, fecal permeability markers) and clinical endpoints.
Study Information
- Study Type
- Case-control
- Research Domain
- Pathophysiology
- Evidence Level
- V - Preclinical mechanistic evidence integrating animal and in vitro experiments with human sample correlations
- Study Design
- OTHER